Teva Gets FDA Green Light For 1st Lexapro Generic

Law360, New York (March 14, 2012, 5:13 PM EDT) -- Teva Pharmaceutical Industries Ltd. on Wednesday won approval from the U.S. Food and Drug Administration to market a generic version of the widely used antidepressant Lexapro, giving the company exclusive rights to sell the generic version for the next 180 days.

Used to treat major depressive disorder in adults and adolescents and generalize anxiety disorder in adults, Lexapro has racked up billions in sales during its time on the U.S. market, Teva said.

Teva has begun its commercial launch of its generic escitalopram oxalate tablets, the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.